肾髓质海绵肾 中国就医指南

Medullary Sponge Kidney (MSK) is a rare, congenital renal malformation characterized by cystic dilatation of the collecting ducts in the renal medulla and papillae, giving the kidney a sponge-like appearance on imaging. It is typically bilateral and non-progressive, though complications—particularly nephrocalcinosis, recurrent nephrolithiasis (calcium phosphate or calcium oxalate stones), and distal renal tubular acidosis—can significantly impact long-term renal health. The pathogenesis remains incompletely understood but is believed to involve abnormal embryonic development of the medullary collecting ducts, possibly due to localized defects in ureteric bud–metanephric mesenchyme interaction or dysregulated apoptosis during ductal maturation. Genetic factors may contribute, with some familial cases reported and associations noted with mutations in the GDNF or RET pathways; however, MSK is predominantly sporadic and not linked to a single high-penetrance gene. Epidemiologically, MSK affects approximately 0.5–1% of the general population undergoing abdominal CT or intravenous urography, though many remain undiagnosed due to asymptomatic presentation. It is equally distributed across sexes and typically identified in adulthood (30–50 years), often incidentally during evaluation for kidney stones or hematuria. Risk factors include a personal or family history of nephrocalcinosis or recurrent calcium-based urolithiasis; no strong environmental or lifestyle risk factors have been established. Importantly, MSK is not associated with systemic disease or progressive chronic kidney disease in most patients—but recurrent stone episodes, urinary tract infections, and chronic pain can substantially impair quality of life. Patients frequently report anxiety around stone passage, limitations in physical activity, disrupted sleep, reduced work productivity, and emotional distress related to unpredictable flares. While renal function usually remains preserved, repeated obstruction or infection may rarely lead to chronic kidney disease stage 3 or higher. Management focuses on prevention: aggressive hydration (2.5–3 L/day), dietary modification (moderate sodium and animal protein restriction, adequate calcium intake), urine alkalinization when indicated, and metabolic evaluation to guide targeted therapy (e.g., thiazides for hypercalciuria, citrate supplementation). Regular monitoring of renal function, stone burden, and acid-base status is essential. Patient education and shared decision-making are cornerstones of care, as MSK requires lifelong vigilance rather than curative intervention.

# 肾髓质海绵肾治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用于无症状、偶发血尿或轻度结石者（占70%以上）：

• •定期随访：泌尿系超声+尿常规+肾功能（每6–12个月），¥280–¥420/次
• •水化干预：每日饮水≥2000 mL，碱化尿液（枸橼酸钾片），药物年费用 ¥600–¥1800
• •结石管理：小结石（<5 mm）予α受体阻滞剂（坦索罗辛）+止痛（布洛芬缓释片），年药费 ¥300–¥900

二、微创介入治疗方案

适用于反复结石梗阻、顽固性血尿或继发感染：

• •输尿管软镜碎石术（F-URS）：单侧集合系统处理，含术前CTU、麻醉、术后复查，¥22,000–¥35,000/次（术前检查费 ¥1,200–¥1,800）
• •经皮肾镜取石术（PCNL）：仅限多发大负荷钙化灶，¥38,000–¥52,000/次

三、复杂/并发症治疗方案

合并慢性肾病（CKD 3期以上）、反复尿路感染或肾乳头坏死者：

• •多学科联合管理（肾内科+泌尿外科+营养科），含24h尿成石分析、代谢评估、个体化预防方案，首年综合管理费 ¥8,500–¥15,000

方案快速选择指南

• •无症状者：首选保守随访（年均¥500内）；
• •年发结石≥2次者：推荐F-URS（性价比最优）；
• •CKD合并反复感染：启动多学科全程管理，避免肾功能恶化。